Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study

A Multicenter, Non-interventional, Two-cohort Study to Describe Real-world Treatment Patterns and Outcomes in Patients With Peripheral T-cell Lymphoma

This study aims to characterize the epidemiology, clinicopathologic features, and survival outcomes of Chinese patients with PTCL; to develop and validate prognostic models to this population; to compare the real-world effectiveness and safety of alternative therapeutic strategies; to elucidate molecular mechanisms underlying treatment resistance and relapse; to identify actionable targets and predictive biomarkers.

Due to disease heterogeneity and variability in clinical practice, establishing a large-scale Chinese PTCL database to characterize real-world treatment patterns and clinical outcomes is a critical undertaking. A retrospective cohort will define the clinical epidemiology of the disease, while a prospective cohort will delineate current treatment pathways and outcomes in routine practice and explore the molecular features of PTCL in the Chinese population, thereby providing evidence to support precision therapy.

Inclusion Criteria:

• Age ≥18 years, with a histopathologic diagnosis of PTCL (any subtype per WHO 2016 classification of hematolymphoid neoplasms).
• Cohort A: Patients diagnosed and treated at participating centers between 2010 and 2024.
• Cohort B: Patients newly diagnosed from October 2025 onward.
• Availability of basic diagnostic and treatment records .

Exclusion Criteria:

• Indeterminate diagnosis or missing pathology report.
• Patients diagnosed at an outside institution who did not receive their primary treatment and follow-up at a participating center.
• Diagnoses of NK/T-cell lymphoma or primary cutaneous T-cell lymphomas.